IPP Bureau
Royal Sense launches multiple products in pharmaceutical category
By IPP Bureau - August 28, 2024
Launches Opentop 40, Opentop D, Opentop L, Opentop Dsr and Cefix 200 which are available for sale
Mastek and Onyx Health partner to accelerate healthcare data interoperability
By IPP Bureau - August 28, 2024
The partnership will provide health plans with an out-of-the-box compliance solution for CMS-9115 and CMS-0057 rules
India's bioeconomy to reach US $300 billion by 2030: Dr. Jitendra Singh
By IPP Bureau - August 27, 2024
The new bioeconomy policy rolled out by the Modi government is set to place India as a global leader in the years to come
EC approves Ordspono for the treatment of relapsed/refractory follicular lymphoma and diffuse large B-cell lymphoma
By IPP Bureau - August 27, 2024
Ordspono is Regeneron’s first approved bispecific antibody and will provide an off-the-shelf option that can be administered in the out-patient setting, with hope for complete remission
Merck receives EC approval for Winrevair for treatment of PAH
By IPP Bureau - August 27, 2024
Winrevair is the first activin signaling inhibitor therapy for PAH approved in Europe
Mangalam Drugs & Organics awarded US$ 274,800 grant by MMV
By IPP Bureau - August 27, 2024
The grant is designated for the research and development of Pyronaridine
Shilpa Medicare receives USFDA approval for Bortezomib injection
By IPP Bureau - August 27, 2024
Bortezomib Injection is approved for subcutaneous or intravenous use. It is available as a single dose vial of 3.5 mg/1.4 mL (2.5 mg/mL)
Roche’s PiaSky approved in the EU as the first monthly subcutaneous treatment for people with PNH
By IPP Bureau - August 27, 2024
PiaSky advances C5 inhibition through innovative recycling technology, which enables its monthly SC administration
Bristol Myers Squibb to present data across cardiovascular portfolio at ECS 2024
By IPP Bureau - August 27, 2024
New analyses, including presentations on mavacamten, apixaban and milvexian, further solidify the company's strength and expertise as a leader in cardiovascular diseases
Pfizer launches digital platform ‘PfizerForAll’
By IPP Bureau - August 27, 2024
PfizerForAll works within the existing healthcare system and through a growing network of partners to simplify access via established channels and to close gaps in care
Merck announces Phase 3 trial initiation for Bomedemstat
By IPP Bureau - August 27, 2024
The initiation of a second Phase 3 clinical trial for bomedemstat demonstrates company’s commitment to advancing research in myeloproliferative neoplasms (MPNs)
Akums appoints Amrut Medhekar as CEO - CDMO Business
By IPP Bureau - August 26, 2024
e brings over 27+ years of rich pharmaceutical experience
Akums Q1 FY25 revenue up 5.1%
By IPP Bureau - August 26, 2024
The new Injectable Facility housed in Akums Healthcare started commercial production on 22nd August 2024, with a capacity of 362 million units annually
Honeywell launches quality management system HQMR for Life Sciences industry
By IPP Bureau - August 26, 2024
Honeywell Quality Management Review helps manufacturers boost efficiency and quality compliance
Shilpa Medicare announces positive outcome of Phase 3 studies of NorUDCA
By IPP Bureau - August 26, 2024
Nor UDCA is likely to be a first-in-class treatment option for NAFLD in India
